Expansion into the Chinese Market

The agreement grants the Hainan-based partner exclusive rights to sell Vuno's AI cardiac arrest prediction medical device in the province. Vuno has developed AI algorithms that analyze patient data to predict the risk of cardiac arrest, supporting early intervention by medical staff.

The company has been pursuing regulatory approvals and commercialization of its AI medical devices in multiple markets, and the Hainan agreement marks a step in its overseas expansion strategy.

Details Remain Limited

Further specifics of the agreement — including the name of the local partner, contract duration, and financial terms — were not disclosed in the available information. The scope of the exclusivity is limited to Hainan Province and does not cover mainland China as a whole.

Hainan operates as a special zone with distinct regulatory and trade policies, a framework that has attracted foreign medical technology deployments.

The claim that Vuno has concluded an exclusive distribution agreement for its AI cardiac arrest prediction medical device in Hainan Province is True.